Real-World Evidence of Efficacy and Safety of Levonadifloxacin (Oral and IV) in the Management of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Findings of a Retrospective, Multi-Center Study.

Autor:	Mehta KD; Medical Affairs, Wockhardt Ltd., Mumbai, IND., Sharma JB; Medical Oncology, Action Cancer Hospital, New Delhi, IND., Anand A; Critical Care and Emergency Medicine, Sir Ganga Ram City Hospital (SGRH), New Delhi, IND., Reddy N PK; Critical Care Medicine, CARE Hospitals, Hyderabad, IND., Kadam P; Surgery, Ruby Hall, Pune, IND., Debnath K; Medical Affairs, Clinical Operations, Pharmacovigilance (PV) and Regulatory, Wockhardt Ltd., Mumbai, IND., Bhapkar S; Medical Affairs, Wockhardt Ltd., Mumbai, IND., Thampi BM; Medical Affairs, Wockhardt Ltd., Mumbai, IND.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2022 Apr 20; Vol. 14 (4), pp. e24299. Date of Electronic Publication: 2022 Apr 20 (Print Publication: 2022).
DOI:	10.7759/cureus.24299
Abstrakt:	Background Antimicrobial resistance by bacteria poses a substantial threat to the success in the treatment of acute bacterial skin and skin structure infections (ABSSSI). Levonadifloxacin is a novel benzoquinolizine subclass of quinolone which has a broad spectrum of activity, available in both oral and intravenous formulations for the treatment of skin structure infections caused by Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA). Patients and methods This prescription event monitoring study captured data of 227 patients receiving levonadifloxacin (oral and/or IV) in a real-world setting to assess the safety and efficacy in the treatment of ABSSSI. Study outcomes were a clinical and microbial success at the end of therapy and safety was assessed based on adverse events reported. Results One hundred and forty patients received IV levonadifloxacin therapy, 76 patients received oral alalevonadifloxacin, and 11 received IV followed by oral therapy. The mean duration of therapy was 7.3 days. Out of 227 patients, MRSA isolates were identified in 79 patients. Clinical success rates with oral, IV, and IV followed by oral levonadifloxacin therapy were 97.3%, 97.8%, and 100% respectively. The overall microbial success rate was 99.2% and only two patients reported two adverse events. Conclusions The excellent safety and efficacy profile of levonadifloxacin on oral and/or intravenous therapy, makes it a desirable treatment modality for management of ABSSSI. Unique features of levonadifloxacin such as availability of both IV and oral form, minimal drug-drug interactions, exemption from dosage adjustment in renal and hepatic impaired patients and a broad spectrum of coverage, makes it a suitable agent meeting several unmet clinical needs in contemporary patients. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2022, Mehta et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu